nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—TYMS—pancreatic cancer	0.476	1	CbGaD
Pralatrexate—TYMS—Gemcitabine—pancreatic cancer	0.2	0.539	CbGbCtD
Pralatrexate—TYMS—Fluorouracil—pancreatic cancer	0.171	0.461	CbGbCtD
Pralatrexate—Pemetrexed—SLC29A1—pancreatic cancer	0.00191	0.387	CrCbGaD
Pralatrexate—TYMS—Paclitaxel—Docetaxel—pancreatic cancer	0.00112	0.451	CbGdCrCtD
Pralatrexate—Raltitrexed—TYMS—pancreatic cancer	0.00112	0.227	CrCbGaD
Pralatrexate—TYMS—Gefitinib—Erlotinib—pancreatic cancer	0.00108	0.433	CbGdCrCtD
Pralatrexate—Neoplasm malignant—Sunitinib—pancreatic cancer	0.000961	0.0125	CcSEcCtD
Pralatrexate—Leucovorin—TYMS—pancreatic cancer	0.00085	0.172	CrCbGaD
Pralatrexate—Sepsis—Tamoxifen—pancreatic cancer	0.000831	0.0108	CcSEcCtD
Pralatrexate—Sepsis—Erlotinib—pancreatic cancer	0.000822	0.0107	CcSEcCtD
Pralatrexate—Neoplasm malignant—Irinotecan—pancreatic cancer	0.000791	0.0103	CcSEcCtD
Pralatrexate—Neoplasm malignant—Gemcitabine—pancreatic cancer	0.000771	0.01	CcSEcCtD
Pralatrexate—Sepsis—Sunitinib—pancreatic cancer	0.000712	0.00926	CcSEcCtD
Pralatrexate—Pharyngolaryngeal pain—Docetaxel—pancreatic cancer	0.000692	0.009	CcSEcCtD
Pralatrexate—Laryngeal pain—Docetaxel—pancreatic cancer	0.000685	0.00891	CcSEcCtD
Pralatrexate—Pemetrexed—TYMS—pancreatic cancer	0.000679	0.138	CrCbGaD
Pralatrexate—Liver function test abnormal—Tamoxifen—pancreatic cancer	0.000642	0.00835	CcSEcCtD
Pralatrexate—Dehydration—Erlotinib—pancreatic cancer	0.00064	0.00832	CcSEcCtD
Pralatrexate—Hypokalaemia—Erlotinib—pancreatic cancer	0.000626	0.00814	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Erlotinib—pancreatic cancer	0.000619	0.00806	CcSEcCtD
Pralatrexate—Pain in extremity—Sunitinib—pancreatic cancer	0.000595	0.00774	CcSEcCtD
Pralatrexate—Sepsis—Irinotecan—pancreatic cancer	0.000586	0.00763	CcSEcCtD
Pralatrexate—Sepsis—Gemcitabine—pancreatic cancer	0.000571	0.00743	CcSEcCtD
Pralatrexate—Pancytopenia—Tamoxifen—pancreatic cancer	0.000571	0.00742	CcSEcCtD
Pralatrexate—Neutropenia—Tamoxifen—pancreatic cancer	0.000562	0.00731	CcSEcCtD
Pralatrexate—Sepsis—Fluorouracil—pancreatic cancer	0.000562	0.0073	CcSEcCtD
Pralatrexate—Neutropenia—Erlotinib—pancreatic cancer	0.000556	0.00723	CcSEcCtD
Pralatrexate—Dehydration—Sunitinib—pancreatic cancer	0.000554	0.0072	CcSEcCtD
Pralatrexate—Liver function test abnormal—Sunitinib—pancreatic cancer	0.00055	0.00715	CcSEcCtD
Pralatrexate—Hypokalaemia—Sunitinib—pancreatic cancer	0.000542	0.00705	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Sunitinib—pancreatic cancer	0.000536	0.00697	CcSEcCtD
Pralatrexate—Epistaxis—Erlotinib—pancreatic cancer	0.0005	0.0065	CcSEcCtD
Pralatrexate—Pancytopenia—Sunitinib—pancreatic cancer	0.000489	0.00636	CcSEcCtD
Pralatrexate—Neutropenia—Sunitinib—pancreatic cancer	0.000481	0.00626	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Sunitinib—pancreatic cancer	0.000478	0.00622	CcSEcCtD
Pralatrexate—Dehydration—Irinotecan—pancreatic cancer	0.000456	0.00593	CcSEcCtD
Pralatrexate—Hypokalaemia—Irinotecan—pancreatic cancer	0.000446	0.00581	CcSEcCtD
Pralatrexate—Liver function test abnormal—Gemcitabine—pancreatic cancer	0.000441	0.00574	CcSEcCtD
Pralatrexate—Hypokalaemia—Gemcitabine—pancreatic cancer	0.000435	0.00566	CcSEcCtD
Pralatrexate—Epistaxis—Sunitinib—pancreatic cancer	0.000433	0.00563	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Gemcitabine—pancreatic cancer	0.00043	0.0056	CcSEcCtD
Pralatrexate—Sepsis—Docetaxel—pancreatic cancer	0.000405	0.00527	CcSEcCtD
Pralatrexate—Back pain—Tamoxifen—pancreatic cancer	0.000405	0.00527	CcSEcCtD
Pralatrexate—Back pain—Erlotinib—pancreatic cancer	0.000401	0.00521	CcSEcCtD
Pralatrexate—Neutropenia—Irinotecan—pancreatic cancer	0.000396	0.00516	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Irinotecan—pancreatic cancer	0.000394	0.00512	CcSEcCtD
Pralatrexate—Pancytopenia—Gemcitabine—pancreatic cancer	0.000392	0.0051	CcSEcCtD
Pralatrexate—Anaemia—Tamoxifen—pancreatic cancer	0.000387	0.00503	CcSEcCtD
Pralatrexate—Neutropenia—Gemcitabine—pancreatic cancer	0.000386	0.00502	CcSEcCtD
Pralatrexate—Pancytopenia—Fluorouracil—pancreatic cancer	0.000386	0.00501	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Fluorouracil—pancreatic cancer	0.000377	0.00491	CcSEcCtD
Pralatrexate—Leukopenia—Tamoxifen—pancreatic cancer	0.000375	0.00487	CcSEcCtD
Pralatrexate—Methotrexate—TYMS—pancreatic cancer	0.000375	0.076	CrCbGaD
Pralatrexate—Neoplasm malignant—Epirubicin—pancreatic cancer	0.000369	0.0048	CcSEcCtD
Pralatrexate—Cough—Tamoxifen—pancreatic cancer	0.000365	0.00475	CcSEcCtD
Pralatrexate—Cough—Erlotinib—pancreatic cancer	0.000361	0.0047	CcSEcCtD
Pralatrexate—Back pain—Sunitinib—pancreatic cancer	0.000347	0.00451	CcSEcCtD
Pralatrexate—Oedema—Tamoxifen—pancreatic cancer	0.000342	0.00444	CcSEcCtD
Pralatrexate—Epistaxis—Fluorouracil—pancreatic cancer	0.000341	0.00444	CcSEcCtD
Pralatrexate—Neoplasm malignant—Doxorubicin—pancreatic cancer	0.000341	0.00444	CcSEcCtD
Pralatrexate—Pain in extremity—Docetaxel—pancreatic cancer	0.000339	0.00441	CcSEcCtD
Pralatrexate—Oedema—Erlotinib—pancreatic cancer	0.000338	0.0044	CcSEcCtD
Pralatrexate—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.000335	0.00435	CcSEcCtD
Pralatrexate—Anaemia—Sunitinib—pancreatic cancer	0.000331	0.00431	CcSEcCtD
Pralatrexate—Thrombocytopenia—Erlotinib—pancreatic cancer	0.000331	0.0043	CcSEcCtD
Pralatrexate—Anorexia—Tamoxifen—pancreatic cancer	0.000326	0.00424	CcSEcCtD
Pralatrexate—Anorexia—Erlotinib—pancreatic cancer	0.000322	0.00419	CcSEcCtD
Pralatrexate—Leukopenia—Sunitinib—pancreatic cancer	0.000321	0.00417	CcSEcCtD
Pralatrexate—Dehydration—Docetaxel—pancreatic cancer	0.000315	0.0041	CcSEcCtD
Pralatrexate—Liver function test abnormal—Docetaxel—pancreatic cancer	0.000313	0.00407	CcSEcCtD
Pralatrexate—Cough—Sunitinib—pancreatic cancer	0.000313	0.00407	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Docetaxel—pancreatic cancer	0.000305	0.00397	CcSEcCtD
Pralatrexate—Dyspnoea—Tamoxifen—pancreatic cancer	0.000305	0.00396	CcSEcCtD
Pralatrexate—Dyspnoea—Erlotinib—pancreatic cancer	0.000301	0.00392	CcSEcCtD
Pralatrexate—Decreased appetite—Tamoxifen—pancreatic cancer	0.000297	0.00386	CcSEcCtD
Pralatrexate—Fatigue—Tamoxifen—pancreatic cancer	0.000295	0.00383	CcSEcCtD
Pralatrexate—Decreased appetite—Erlotinib—pancreatic cancer	0.000294	0.00382	CcSEcCtD
Pralatrexate—Oedema—Sunitinib—pancreatic cancer	0.000293	0.00381	CcSEcCtD
Pralatrexate—Constipation—Tamoxifen—pancreatic cancer	0.000292	0.0038	CcSEcCtD
Pralatrexate—Fatigue—Erlotinib—pancreatic cancer	0.000291	0.00379	CcSEcCtD
Pralatrexate—TYMS—Azacitidine—Gemcitabine—pancreatic cancer	0.000291	0.117	CbGdCrCtD
Pralatrexate—Constipation—Erlotinib—pancreatic cancer	0.000289	0.00376	CcSEcCtD
Pralatrexate—Thrombocytopenia—Sunitinib—pancreatic cancer	0.000287	0.00373	CcSEcCtD
Pralatrexate—Back pain—Irinotecan—pancreatic cancer	0.000286	0.00372	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000279	0.00363	CcSEcCtD
Pralatrexate—Anorexia—Sunitinib—pancreatic cancer	0.000279	0.00363	CcSEcCtD
Pralatrexate—Back pain—Gemcitabine—pancreatic cancer	0.000278	0.00362	CcSEcCtD
Pralatrexate—Pancytopenia—Docetaxel—pancreatic cancer	0.000278	0.00362	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000276	0.0036	CcSEcCtD
Pralatrexate—Neutropenia—Docetaxel—pancreatic cancer	0.000274	0.00356	CcSEcCtD
Pralatrexate—Sepsis—Epirubicin—pancreatic cancer	0.000273	0.00356	CcSEcCtD
Pralatrexate—Anaemia—Irinotecan—pancreatic cancer	0.000273	0.00355	CcSEcCtD
Pralatrexate—Abdominal pain—Tamoxifen—pancreatic cancer	0.00027	0.00351	CcSEcCtD
Pralatrexate—Abdominal pain—Erlotinib—pancreatic cancer	0.000267	0.00348	CcSEcCtD
Pralatrexate—Body temperature increased—Erlotinib—pancreatic cancer	0.000267	0.00348	CcSEcCtD
Pralatrexate—Anaemia—Gemcitabine—pancreatic cancer	0.000266	0.00346	CcSEcCtD
Pralatrexate—Leukopenia—Irinotecan—pancreatic cancer	0.000264	0.00344	CcSEcCtD
Pralatrexate—Anaemia—Fluorouracil—pancreatic cancer	0.000261	0.0034	CcSEcCtD
Pralatrexate—Dyspnoea—Sunitinib—pancreatic cancer	0.000261	0.00339	CcSEcCtD
Pralatrexate—Cough—Irinotecan—pancreatic cancer	0.000258	0.00335	CcSEcCtD
Pralatrexate—Leukopenia—Gemcitabine—pancreatic cancer	0.000258	0.00335	CcSEcCtD
Pralatrexate—Decreased appetite—Sunitinib—pancreatic cancer	0.000254	0.00331	CcSEcCtD
Pralatrexate—Leukopenia—Fluorouracil—pancreatic cancer	0.000253	0.00329	CcSEcCtD
Pralatrexate—Sepsis—Doxorubicin—pancreatic cancer	0.000253	0.00329	CcSEcCtD
Pralatrexate—Fatigue—Sunitinib—pancreatic cancer	0.000252	0.00328	CcSEcCtD
Pralatrexate—Cough—Gemcitabine—pancreatic cancer	0.000251	0.00327	CcSEcCtD
Pralatrexate—Constipation—Sunitinib—pancreatic cancer	0.00025	0.00325	CcSEcCtD
Pralatrexate—Epistaxis—Docetaxel—pancreatic cancer	0.000246	0.00321	CcSEcCtD
Pralatrexate—Asthenia—Tamoxifen—pancreatic cancer	0.000245	0.00319	CcSEcCtD
Pralatrexate—Asthenia—Erlotinib—pancreatic cancer	0.000243	0.00315	CcSEcCtD
Pralatrexate—Pruritus—Tamoxifen—pancreatic cancer	0.000242	0.00314	CcSEcCtD
Pralatrexate—Oedema—Irinotecan—pancreatic cancer	0.000241	0.00314	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000239	0.00311	CcSEcCtD
Pralatrexate—Pruritus—Erlotinib—pancreatic cancer	0.000239	0.00311	CcSEcCtD
Pralatrexate—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000236	0.00307	CcSEcCtD
Pralatrexate—Oedema—Gemcitabine—pancreatic cancer	0.000235	0.00305	CcSEcCtD
Pralatrexate—Diarrhoea—Tamoxifen—pancreatic cancer	0.000234	0.00304	CcSEcCtD
Pralatrexate—Body temperature increased—Sunitinib—pancreatic cancer	0.000231	0.00301	CcSEcCtD
Pralatrexate—Abdominal pain—Sunitinib—pancreatic cancer	0.000231	0.00301	CcSEcCtD
Pralatrexate—Diarrhoea—Erlotinib—pancreatic cancer	0.000231	0.00301	CcSEcCtD
Pralatrexate—Oedema—Fluorouracil—pancreatic cancer	0.000231	0.003	CcSEcCtD
Pralatrexate—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.00023	0.00299	CcSEcCtD
Pralatrexate—Anorexia—Irinotecan—pancreatic cancer	0.00023	0.00299	CcSEcCtD
Pralatrexate—Pain in extremity—Epirubicin—pancreatic cancer	0.000229	0.00297	CcSEcCtD
Pralatrexate—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000226	0.00294	CcSEcCtD
Pralatrexate—Tachycardia—Fluorouracil—pancreatic cancer	0.000225	0.00293	CcSEcCtD
Pralatrexate—Anorexia—Gemcitabine—pancreatic cancer	0.000224	0.00291	CcSEcCtD
Pralatrexate—Anorexia—Fluorouracil—pancreatic cancer	0.00022	0.00286	CcSEcCtD
Pralatrexate—Vomiting—Tamoxifen—pancreatic cancer	0.000217	0.00283	CcSEcCtD
Pralatrexate—Rash—Tamoxifen—pancreatic cancer	0.000215	0.0028	CcSEcCtD
Pralatrexate—Dermatitis—Tamoxifen—pancreatic cancer	0.000215	0.0028	CcSEcCtD
Pralatrexate—Vomiting—Erlotinib—pancreatic cancer	0.000215	0.0028	CcSEcCtD
Pralatrexate—Dyspnoea—Irinotecan—pancreatic cancer	0.000215	0.0028	CcSEcCtD
Pralatrexate—Rash—Erlotinib—pancreatic cancer	0.000213	0.00277	CcSEcCtD
Pralatrexate—Dermatitis—Erlotinib—pancreatic cancer	0.000213	0.00277	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—pancreatic cancer	0.000213	0.00277	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—pancreatic cancer	0.000212	0.00275	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000211	0.00275	CcSEcCtD
Pralatrexate—Asthenia—Sunitinib—pancreatic cancer	0.00021	0.00273	CcSEcCtD
Pralatrexate—Decreased appetite—Irinotecan—pancreatic cancer	0.00021	0.00273	CcSEcCtD
Pralatrexate—Dyspnoea—Gemcitabine—pancreatic cancer	0.000209	0.00272	CcSEcCtD
Pralatrexate—Hypokalaemia—Epirubicin—pancreatic cancer	0.000208	0.00271	CcSEcCtD
Pralatrexate—Fatigue—Irinotecan—pancreatic cancer	0.000208	0.0027	CcSEcCtD
Pralatrexate—Pruritus—Sunitinib—pancreatic cancer	0.000207	0.00269	CcSEcCtD
Pralatrexate—Constipation—Irinotecan—pancreatic cancer	0.000206	0.00268	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000206	0.00268	CcSEcCtD
Pralatrexate—Dyspnoea—Fluorouracil—pancreatic cancer	0.000206	0.00268	CcSEcCtD
Pralatrexate—Decreased appetite—Gemcitabine—pancreatic cancer	0.000204	0.00265	CcSEcCtD
Pralatrexate—Nausea—Tamoxifen—pancreatic cancer	0.000203	0.00264	CcSEcCtD
Pralatrexate—Fatigue—Gemcitabine—pancreatic cancer	0.000202	0.00263	CcSEcCtD
Pralatrexate—Constipation—Gemcitabine—pancreatic cancer	0.000201	0.00261	CcSEcCtD
Pralatrexate—Nausea—Erlotinib—pancreatic cancer	0.000201	0.00261	CcSEcCtD
Pralatrexate—Decreased appetite—Fluorouracil—pancreatic cancer	0.000201	0.00261	CcSEcCtD
Pralatrexate—Diarrhoea—Sunitinib—pancreatic cancer	0.0002	0.0026	CcSEcCtD
Pralatrexate—Back pain—Docetaxel—pancreatic cancer	0.000198	0.00257	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000197	0.00256	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—pancreatic cancer	0.000197	0.00256	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000195	0.00254	CcSEcCtD
Pralatrexate—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000193	0.0025	CcSEcCtD
Pralatrexate—Abdominal pain—Irinotecan—pancreatic cancer	0.000191	0.00248	CcSEcCtD
Pralatrexate—Body temperature increased—Irinotecan—pancreatic cancer	0.000191	0.00248	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000191	0.00248	CcSEcCtD
Pralatrexate—Anaemia—Docetaxel—pancreatic cancer	0.000189	0.00245	CcSEcCtD
Pralatrexate—Pancytopenia—Epirubicin—pancreatic cancer	0.000188	0.00244	CcSEcCtD
Pralatrexate—Vomiting—Sunitinib—pancreatic cancer	0.000186	0.00242	CcSEcCtD
Pralatrexate—Body temperature increased—Gemcitabine—pancreatic cancer	0.000186	0.00241	CcSEcCtD
Pralatrexate—Neutropenia—Epirubicin—pancreatic cancer	0.000185	0.0024	CcSEcCtD
Pralatrexate—Rash—Sunitinib—pancreatic cancer	0.000185	0.0024	CcSEcCtD
Pralatrexate—Dermatitis—Sunitinib—pancreatic cancer	0.000184	0.0024	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000184	0.00239	CcSEcCtD
Pralatrexate—Leukopenia—Docetaxel—pancreatic cancer	0.000183	0.00238	CcSEcCtD
Pralatrexate—Body temperature increased—Fluorouracil—pancreatic cancer	0.000183	0.00237	CcSEcCtD
Pralatrexate—Cough—Docetaxel—pancreatic cancer	0.000178	0.00232	CcSEcCtD
Pralatrexate—Nausea—Sunitinib—pancreatic cancer	0.000174	0.00226	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—pancreatic cancer	0.000174	0.00226	CcSEcCtD
Pralatrexate—Asthenia—Irinotecan—pancreatic cancer	0.000173	0.00225	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—pancreatic cancer	0.000171	0.00222	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.00017	0.00221	CcSEcCtD
Pralatrexate—Asthenia—Gemcitabine—pancreatic cancer	0.000168	0.00219	CcSEcCtD
Pralatrexate—Oedema—Docetaxel—pancreatic cancer	0.000167	0.00217	CcSEcCtD
Pralatrexate—Epistaxis—Epirubicin—pancreatic cancer	0.000166	0.00216	CcSEcCtD
Pralatrexate—Pruritus—Gemcitabine—pancreatic cancer	0.000166	0.00216	CcSEcCtD
Pralatrexate—Diarrhoea—Irinotecan—pancreatic cancer	0.000165	0.00215	CcSEcCtD
Pralatrexate—Pruritus—Fluorouracil—pancreatic cancer	0.000163	0.00212	CcSEcCtD
Pralatrexate—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000163	0.00212	CcSEcCtD
Pralatrexate—Tachycardia—Docetaxel—pancreatic cancer	0.000163	0.00212	CcSEcCtD
Pralatrexate—Diarrhoea—Gemcitabine—pancreatic cancer	0.000161	0.00209	CcSEcCtD
Pralatrexate—Anorexia—Docetaxel—pancreatic cancer	0.000159	0.00207	CcSEcCtD
Pralatrexate—Diarrhoea—Fluorouracil—pancreatic cancer	0.000158	0.00205	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—RBBP8—pancreatic cancer	0.000155	0.0023	CbGpPWpGaD
Pralatrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—pancreatic cancer	0.000155	0.0023	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PPP2R5B—pancreatic cancer	0.000155	0.00229	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SLC2A2—pancreatic cancer	0.000155	0.00229	CbGpPWpGaD
Pralatrexate—Epistaxis—Doxorubicin—pancreatic cancer	0.000154	0.002	CcSEcCtD
Pralatrexate—Vomiting—Irinotecan—pancreatic cancer	0.000153	0.00199	CcSEcCtD
Pralatrexate—Rash—Irinotecan—pancreatic cancer	0.000152	0.00198	CcSEcCtD
Pralatrexate—Dermatitis—Irinotecan—pancreatic cancer	0.000152	0.00197	CcSEcCtD
Pralatrexate—FPGS—Disease—HEY1—pancreatic cancer	0.000151	0.00224	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	0.000151	0.00223	CbGpPWpGaD
Pralatrexate—Vomiting—Gemcitabine—pancreatic cancer	0.000149	0.00194	CcSEcCtD
Pralatrexate—Dyspnoea—Docetaxel—pancreatic cancer	0.000149	0.00193	CcSEcCtD
Pralatrexate—SLC19A1—Disease—SHH—pancreatic cancer	0.000148	0.0022	CbGpPWpGaD
Pralatrexate—Rash—Gemcitabine—pancreatic cancer	0.000148	0.00193	CcSEcCtD
Pralatrexate—Dermatitis—Gemcitabine—pancreatic cancer	0.000148	0.00192	CcSEcCtD
Pralatrexate—Vomiting—Fluorouracil—pancreatic cancer	0.000147	0.00191	CcSEcCtD
Pralatrexate—SLC19A1—Disease—IAPP—pancreatic cancer	0.000147	0.00217	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—TYMP—pancreatic cancer	0.000146	0.00217	CbGpPWpGaD
Pralatrexate—Rash—Fluorouracil—pancreatic cancer	0.000146	0.00189	CcSEcCtD
Pralatrexate—Dermatitis—Fluorouracil—pancreatic cancer	0.000145	0.00189	CcSEcCtD
Pralatrexate—Decreased appetite—Docetaxel—pancreatic cancer	0.000145	0.00188	CcSEcCtD
Pralatrexate—Fatigue—Docetaxel—pancreatic cancer	0.000144	0.00187	CcSEcCtD
Pralatrexate—Nausea—Irinotecan—pancreatic cancer	0.000143	0.00186	CcSEcCtD
Pralatrexate—Constipation—Docetaxel—pancreatic cancer	0.000143	0.00185	CcSEcCtD
Pralatrexate—SLC19A1—Disease—HSPA1B—pancreatic cancer	0.000141	0.00208	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CCND1—pancreatic cancer	0.00014	0.00208	CbGpPWpGaD
Pralatrexate—Nausea—Gemcitabine—pancreatic cancer	0.000139	0.00181	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—GLP1R—pancreatic cancer	0.000139	0.00205	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—PPP2R5B—pancreatic cancer	0.000138	0.00205	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—FOXM1—pancreatic cancer	0.000138	0.00204	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—RB1—pancreatic cancer	0.000138	0.00204	CbGpPWpGaD
Pralatrexate—Nausea—Fluorouracil—pancreatic cancer	0.000137	0.00178	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—DPYD—pancreatic cancer	0.000136	0.00202	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000136	0.00177	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	0.000136	0.00202	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PPP2R5B—pancreatic cancer	0.000135	0.002	CbGpPWpGaD
Pralatrexate—FPGS—Disease—JAG2—pancreatic cancer	0.000134	0.00199	CbGpPWpGaD
Pralatrexate—Back pain—Epirubicin—pancreatic cancer	0.000133	0.00173	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—RB1—pancreatic cancer	0.000133	0.00197	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MEN1—pancreatic cancer	0.000132	0.00196	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	0.000132	0.00195	CbGpPWpGaD
Pralatrexate—Abdominal pain—Docetaxel—pancreatic cancer	0.000132	0.00171	CcSEcCtD
Pralatrexate—Body temperature increased—Docetaxel—pancreatic cancer	0.000132	0.00171	CcSEcCtD
Pralatrexate—FPGS—Disease—SLC2A2—pancreatic cancer	0.000131	0.00195	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TNF—pancreatic cancer	0.000131	0.00193	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—SLC2A2—pancreatic cancer	0.000129	0.00192	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—MYC—pancreatic cancer	0.000129	0.00192	CbGpPWpGaD
Pralatrexate—Anaemia—Epirubicin—pancreatic cancer	0.000127	0.00166	CcSEcCtD
Pralatrexate—FPGS—Disease—SHH—pancreatic cancer	0.000126	0.00187	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—JAG1—pancreatic cancer	0.000126	0.00187	CbGpPWpGaD
Pralatrexate—FPGS—Disease—IAPP—pancreatic cancer	0.000125	0.00185	CbGpPWpGaD
Pralatrexate—Leukopenia—Epirubicin—pancreatic cancer	0.000123	0.0016	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—FOXM1—pancreatic cancer	0.000123	0.00183	CbGpPWpGaD
Pralatrexate—Back pain—Doxorubicin—pancreatic cancer	0.000123	0.0016	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CCND1—pancreatic cancer	0.000122	0.00181	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—PPP2R5B—pancreatic cancer	0.000121	0.00179	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—FOXM1—pancreatic cancer	0.00012	0.00178	CbGpPWpGaD
Pralatrexate—Cough—Epirubicin—pancreatic cancer	0.00012	0.00156	CcSEcCtD
Pralatrexate—SLC19A1—Disease—CD44—pancreatic cancer	0.00012	0.00177	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HSPA1B—pancreatic cancer	0.00012	0.00177	CbGpPWpGaD
Pralatrexate—Asthenia—Docetaxel—pancreatic cancer	0.00012	0.00155	CcSEcCtD
Pralatrexate—SLC19A1—Disease—HSPA1A—pancreatic cancer	0.000119	0.00176	CbGpPWpGaD
Pralatrexate—Pruritus—Docetaxel—pancreatic cancer	0.000118	0.00153	CcSEcCtD
Pralatrexate—FPGS—Metabolism—GLP1R—pancreatic cancer	0.000118	0.00175	CbGpPWpGaD
Pralatrexate—Anaemia—Doxorubicin—pancreatic cancer	0.000118	0.00153	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—pancreatic cancer	0.000117	0.00173	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—DPYD—pancreatic cancer	0.000116	0.00172	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—RB1—pancreatic cancer	0.000116	0.00172	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TP53—pancreatic cancer	0.000115	0.00171	CbGpPWpGaD
Pralatrexate—Leukopenia—Doxorubicin—pancreatic cancer	0.000114	0.00148	CcSEcCtD
Pralatrexate—Diarrhoea—Docetaxel—pancreatic cancer	0.000114	0.00148	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—MYC—pancreatic cancer	0.000113	0.00167	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—pancreatic cancer	0.000112	0.00167	CbGpPWpGaD
Pralatrexate—Oedema—Epirubicin—pancreatic cancer	0.000112	0.00146	CcSEcCtD
Pralatrexate—Cough—Doxorubicin—pancreatic cancer	0.000111	0.00145	CcSEcCtD
Pralatrexate—Thrombocytopenia—Epirubicin—pancreatic cancer	0.00011	0.00143	CcSEcCtD
Pralatrexate—FPGS—Metabolism—SLC2A2—pancreatic cancer	0.00011	0.00163	CbGpPWpGaD
Pralatrexate—Tachycardia—Epirubicin—pancreatic cancer	0.00011	0.00143	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—FOXM1—pancreatic cancer	0.000108	0.00159	CbGpPWpGaD
Pralatrexate—Anorexia—Epirubicin—pancreatic cancer	0.000107	0.00139	CcSEcCtD
Pralatrexate—FPGS—Disease—JAG1—pancreatic cancer	0.000107	0.00159	CbGpPWpGaD
Pralatrexate—Vomiting—Docetaxel—pancreatic cancer	0.000106	0.00138	CcSEcCtD
Pralatrexate—Rash—Docetaxel—pancreatic cancer	0.000105	0.00137	CcSEcCtD
Pralatrexate—Dermatitis—Docetaxel—pancreatic cancer	0.000105	0.00137	CcSEcCtD
Pralatrexate—Oedema—Doxorubicin—pancreatic cancer	0.000104	0.00135	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—pancreatic cancer	0.000102	0.00151	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000102	0.00132	CcSEcCtD
Pralatrexate—FPGS—Disease—CD44—pancreatic cancer	0.000102	0.00151	CbGpPWpGaD
Pralatrexate—Tachycardia—Doxorubicin—pancreatic cancer	0.000102	0.00132	CcSEcCtD
Pralatrexate—FPGS—Disease—HSPA1A—pancreatic cancer	0.000101	0.0015	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CD44—pancreatic cancer	0.0001	0.00148	CbGpPWpGaD
Pralatrexate—Dyspnoea—Epirubicin—pancreatic cancer	0.0001	0.0013	CcSEcCtD
Pralatrexate—Anorexia—Doxorubicin—pancreatic cancer	9.91e-05	0.00129	CcSEcCtD
Pralatrexate—Nausea—Docetaxel—pancreatic cancer	9.9e-05	0.00129	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCND1—pancreatic cancer	9.86e-05	0.00146	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	9.81e-05	0.00145	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—pancreatic cancer	9.81e-05	0.00145	CbGpPWpGaD
Pralatrexate—Decreased appetite—Epirubicin—pancreatic cancer	9.77e-05	0.00127	CcSEcCtD
Pralatrexate—Fatigue—Epirubicin—pancreatic cancer	9.69e-05	0.00126	CcSEcCtD
Pralatrexate—DHFR—Disease—PRSS1—pancreatic cancer	9.62e-05	0.00143	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ZNRF3—pancreatic cancer	9.62e-05	0.00143	CbGpPWpGaD
Pralatrexate—Constipation—Epirubicin—pancreatic cancer	9.61e-05	0.00125	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—GCG—pancreatic cancer	9.61e-05	0.00142	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SMAD4—pancreatic cancer	9.45e-05	0.0014	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	9.4e-05	0.00139	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—MYC—pancreatic cancer	9.39e-05	0.00139	CbGpPWpGaD
Pralatrexate—Dyspnoea—Doxorubicin—pancreatic cancer	9.27e-05	0.00121	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	9.23e-05	0.00137	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HES1—pancreatic cancer	9.23e-05	0.00137	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Epirubicin—pancreatic cancer	9.19e-05	0.0012	CcSEcCtD
Pralatrexate—Decreased appetite—Doxorubicin—pancreatic cancer	9.04e-05	0.00118	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—STK11—pancreatic cancer	9.03e-05	0.00134	CbGpPWpGaD
Pralatrexate—Fatigue—Doxorubicin—pancreatic cancer	8.97e-05	0.00117	CcSEcCtD
Pralatrexate—Constipation—Doxorubicin—pancreatic cancer	8.89e-05	0.00116	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—pancreatic cancer	8.89e-05	0.00116	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—pancreatic cancer	8.89e-05	0.00116	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—PPARG—pancreatic cancer	8.81e-05	0.0013	CbGpPWpGaD
Pralatrexate—DHFR—Disease—DTX1—pancreatic cancer	8.7e-05	0.00129	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCND1—pancreatic cancer	8.61e-05	0.00127	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CD44—pancreatic cancer	8.52e-05	0.00126	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.5e-05	0.00111	CcSEcCtD
Pralatrexate—Body temperature increased—Doxorubicin—pancreatic cancer	8.22e-05	0.00107	CcSEcCtD
Pralatrexate—Abdominal pain—Doxorubicin—pancreatic cancer	8.22e-05	0.00107	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—MYC—pancreatic cancer	8.19e-05	0.00121	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GCG—pancreatic cancer	8.17e-05	0.00121	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TERT—pancreatic cancer	8.08e-05	0.0012	CbGpPWpGaD
Pralatrexate—Asthenia—Epirubicin—pancreatic cancer	8.06e-05	0.00105	CcSEcCtD
Pralatrexate—DHFR—Metabolism—PRSS1—pancreatic cancer	8.06e-05	0.00119	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	8.06e-05	0.00119	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SMAD4—pancreatic cancer	8.03e-05	0.00119	CbGpPWpGaD
Pralatrexate—Pruritus—Epirubicin—pancreatic cancer	7.95e-05	0.00103	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—pancreatic cancer	7.91e-05	0.00117	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HES1—pancreatic cancer	7.84e-05	0.00116	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—TYMS—pancreatic cancer	7.77e-05	0.00115	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HIF1A—pancreatic cancer	7.73e-05	0.00114	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TSC2—pancreatic cancer	7.71e-05	0.00114	CbGpPWpGaD
Pralatrexate—Diarrhoea—Epirubicin—pancreatic cancer	7.69e-05	0.001	CcSEcCtD
Pralatrexate—FPGS—Metabolism—STK11—pancreatic cancer	7.68e-05	0.00114	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—APOE—pancreatic cancer	7.55e-05	0.00112	CbGpPWpGaD
Pralatrexate—Asthenia—Doxorubicin—pancreatic cancer	7.46e-05	0.00097	CcSEcCtD
Pralatrexate—Pruritus—Doxorubicin—pancreatic cancer	7.36e-05	0.000957	CcSEcCtD
Pralatrexate—DHFR—Disease—DTX4—pancreatic cancer	7.29e-05	0.00108	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	7.22e-05	0.00107	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—TYMS—pancreatic cancer	7.19e-05	0.00106	CbGpPWpGaD
Pralatrexate—Vomiting—Epirubicin—pancreatic cancer	7.15e-05	0.000929	CcSEcCtD
Pralatrexate—Diarrhoea—Doxorubicin—pancreatic cancer	7.12e-05	0.000925	CcSEcCtD
Pralatrexate—DHFR—Disease—PPP2R5B—pancreatic cancer	7.1e-05	0.00105	CbGpPWpGaD
Pralatrexate—Rash—Epirubicin—pancreatic cancer	7.09e-05	0.000922	CcSEcCtD
Pralatrexate—Dermatitis—Epirubicin—pancreatic cancer	7.08e-05	0.000921	CcSEcCtD
Pralatrexate—TYMS—Metabolism—PRSS1—pancreatic cancer	7.03e-05	0.00104	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ARG2—pancreatic cancer	6.99e-05	0.00103	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NOTCH1—pancreatic cancer	6.96e-05	0.00103	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—pancreatic cancer	6.9e-05	0.00102	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TERT—pancreatic cancer	6.87e-05	0.00102	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HEY2—pancreatic cancer	6.83e-05	0.00101	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BRCA2—pancreatic cancer	6.75e-05	0.001	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGF—pancreatic cancer	6.73e-05	0.000997	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	6.7e-05	0.000992	CbGpPWpGaD
Pralatrexate—Nausea—Epirubicin—pancreatic cancer	6.68e-05	0.000868	CcSEcCtD
Pralatrexate—Vomiting—Doxorubicin—pancreatic cancer	6.61e-05	0.00086	CcSEcCtD
Pralatrexate—FPGS—Metabolism—TYMS—pancreatic cancer	6.61e-05	0.000978	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HIF1A—pancreatic cancer	6.57e-05	0.000973	CbGpPWpGaD
Pralatrexate—Rash—Doxorubicin—pancreatic cancer	6.56e-05	0.000853	CcSEcCtD
Pralatrexate—FPGS—Disease—TSC2—pancreatic cancer	6.56e-05	0.000971	CbGpPWpGaD
Pralatrexate—Dermatitis—Doxorubicin—pancreatic cancer	6.55e-05	0.000852	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	6.52e-05	0.000966	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	6.46e-05	0.000956	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TYMS—pancreatic cancer	6.42e-05	0.000951	CbGpPWpGaD
Pralatrexate—FPGS—Disease—APOE—pancreatic cancer	6.42e-05	0.00095	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HEY1—pancreatic cancer	6.32e-05	0.000936	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—APOE—pancreatic cancer	6.32e-05	0.000936	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	6.29e-05	0.000932	CbGpPWpGaD
Pralatrexate—Nausea—Doxorubicin—pancreatic cancer	6.18e-05	0.000803	CcSEcCtD
Pralatrexate—DHFR—Metabolism—TYMP—pancreatic cancer	6.11e-05	0.000905	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ARG2—pancreatic cancer	6.1e-05	0.000903	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—PTEN—pancreatic cancer	6.04e-05	0.000895	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CD—pancreatic cancer	5.99e-05	0.000887	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NOTCH1—pancreatic cancer	5.92e-05	0.000877	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BRCA2—pancreatic cancer	5.89e-05	0.000873	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	5.84e-05	0.000864	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGF—pancreatic cancer	5.72e-05	0.000848	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CG—pancreatic cancer	5.7e-05	0.000845	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	5.68e-05	0.000842	CbGpPWpGaD
Pralatrexate—DHFR—Disease—JAG2—pancreatic cancer	5.61e-05	0.000831	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TERT—pancreatic cancer	5.6e-05	0.000829	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MEN1—pancreatic cancer	5.53e-05	0.000819	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PPARG—pancreatic cancer	5.5e-05	0.000815	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SLC2A2—pancreatic cancer	5.49e-05	0.000813	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—APOE—pancreatic cancer	5.37e-05	0.000796	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—TYMP—pancreatic cancer	5.33e-05	0.000789	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SHH—pancreatic cancer	5.27e-05	0.000781	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	5.23e-05	0.000775	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CB—pancreatic cancer	5.22e-05	0.000773	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	5.22e-05	0.000773	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IAPP—pancreatic cancer	5.21e-05	0.000771	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTGS2—pancreatic cancer	5.17e-05	0.000766	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	5.12e-05	0.000758	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CD—pancreatic cancer	5.09e-05	0.000754	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CD—pancreatic cancer	5.01e-05	0.000743	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HSPA1B—pancreatic cancer	5e-05	0.00074	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GLP1R—pancreatic cancer	4.92e-05	0.000729	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TERT—pancreatic cancer	4.88e-05	0.000723	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	4.87e-05	0.000721	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—RB1—pancreatic cancer	4.87e-05	0.000721	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CG—pancreatic cancer	4.85e-05	0.000718	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—DPYD—pancreatic cancer	4.84e-05	0.000717	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	4.83e-05	0.000716	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PPARG—pancreatic cancer	4.68e-05	0.000693	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CTNNB1—pancreatic cancer	4.63e-05	0.000685	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC2A2—pancreatic cancer	4.6e-05	0.000681	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTEN—pancreatic cancer	4.51e-05	0.000668	CbGpPWpGaD
Pralatrexate—DHFR—Disease—JAG1—pancreatic cancer	4.47e-05	0.000663	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	4.44e-05	0.000658	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CB—pancreatic cancer	4.44e-05	0.000657	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTGS2—pancreatic cancer	4.4e-05	0.000651	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CB—pancreatic cancer	4.37e-05	0.000647	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—RB1—pancreatic cancer	4.36e-05	0.000645	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—pancreatic cancer	4.33e-05	0.000641	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GLP1R—pancreatic cancer	4.3e-05	0.000636	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	4.3e-05	0.000636	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	4.28e-05	0.000634	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CD—pancreatic cancer	4.26e-05	0.000631	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—RB1—pancreatic cancer	4.25e-05	0.000629	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CD44—pancreatic cancer	4.25e-05	0.000629	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—DPYD—pancreatic cancer	4.23e-05	0.000626	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HSPA1A—pancreatic cancer	4.22e-05	0.000625	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SRC—pancreatic cancer	4.18e-05	0.000619	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—pancreatic cancer	4.12e-05	0.000611	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—STAT3—pancreatic cancer	4.03e-05	0.000597	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NRAS—pancreatic cancer	4.02e-05	0.000596	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC2A2—pancreatic cancer	4.01e-05	0.000594	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CTNNB1—pancreatic cancer	3.93e-05	0.000583	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTEN—pancreatic cancer	3.83e-05	0.000568	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2A—pancreatic cancer	3.83e-05	0.000567	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—RB1—pancreatic cancer	3.8e-05	0.000563	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTEN—pancreatic cancer	3.78e-05	0.000559	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—pancreatic cancer	3.75e-05	0.000555	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TGFB1—pancreatic cancer	3.74e-05	0.000554	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	3.74e-05	0.000553	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CB—pancreatic cancer	3.72e-05	0.00055	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS2—pancreatic cancer	3.68e-05	0.000545	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGFR—pancreatic cancer	3.67e-05	0.000543	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	3.63e-05	0.000537	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—pancreatic cancer	3.62e-05	0.000536	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CD44—pancreatic cancer	3.56e-05	0.000527	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SRC—pancreatic cancer	3.56e-05	0.000527	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—pancreatic cancer	3.46e-05	0.000513	CbGpPWpGaD
Pralatrexate—FPGS—Disease—STAT3—pancreatic cancer	3.43e-05	0.000508	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NRAS—pancreatic cancer	3.42e-05	0.000507	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GCG—pancreatic cancer	3.41e-05	0.000505	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SMAD4—pancreatic cancer	3.36e-05	0.000497	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2A—pancreatic cancer	3.34e-05	0.000495	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HES1—pancreatic cancer	3.28e-05	0.000485	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—pancreatic cancer	3.23e-05	0.000479	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTEN—pancreatic cancer	3.21e-05	0.000476	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—STK11—pancreatic cancer	3.21e-05	0.000475	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—pancreatic cancer	3.19e-05	0.000472	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CA—pancreatic cancer	3.18e-05	0.000471	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TGFB1—pancreatic cancer	3.18e-05	0.000471	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—pancreatic cancer	3.16e-05	0.000467	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGFR—pancreatic cancer	3.12e-05	0.000462	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CD44—pancreatic cancer	3.11e-05	0.00046	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GCG—pancreatic cancer	2.98e-05	0.000441	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—pancreatic cancer	2.94e-05	0.000436	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HRAS—pancreatic cancer	2.94e-05	0.000436	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—pancreatic cancer	2.9e-05	0.00043	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TERT—pancreatic cancer	2.87e-05	0.000425	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—pancreatic cancer	2.82e-05	0.000418	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—STK11—pancreatic cancer	2.8e-05	0.000415	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TYMS—pancreatic cancer	2.76e-05	0.000409	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HIF1A—pancreatic cancer	2.75e-05	0.000407	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TSC2—pancreatic cancer	2.74e-05	0.000406	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CA—pancreatic cancer	2.71e-05	0.000401	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APOE—pancreatic cancer	2.68e-05	0.000397	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CA—pancreatic cancer	2.66e-05	0.000395	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—AKT1—pancreatic cancer	2.6e-05	0.000385	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—pancreatic cancer	2.59e-05	0.000384	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—pancreatic cancer	2.53e-05	0.000375	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HRAS—pancreatic cancer	2.5e-05	0.000371	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NOTCH1—pancreatic cancer	2.47e-05	0.000366	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGF—pancreatic cancer	2.39e-05	0.000354	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CA—pancreatic cancer	2.27e-05	0.000335	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—pancreatic cancer	2.26e-05	0.000335	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—APOE—pancreatic cancer	2.24e-05	0.000332	CbGpPWpGaD
Pralatrexate—FPGS—Disease—AKT1—pancreatic cancer	2.21e-05	0.000327	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—AKT1—pancreatic cancer	2.18e-05	0.000322	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—pancreatic cancer	2.13e-05	0.000316	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CD—pancreatic cancer	2.13e-05	0.000315	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CG—pancreatic cancer	2.03e-05	0.0003	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—APOE—pancreatic cancer	1.96e-05	0.00029	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PPARG—pancreatic cancer	1.96e-05	0.00029	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—pancreatic cancer	1.86e-05	0.000275	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CB—pancreatic cancer	1.85e-05	0.000274	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—AKT1—pancreatic cancer	1.85e-05	0.000274	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—pancreatic cancer	1.84e-05	0.000272	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CD—pancreatic cancer	1.78e-05	0.000264	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CG—pancreatic cancer	1.77e-05	0.000262	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPARG—pancreatic cancer	1.71e-05	0.000253	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CTNNB1—pancreatic cancer	1.64e-05	0.000243	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTEN—pancreatic cancer	1.6e-05	0.000237	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CD—pancreatic cancer	1.55e-05	0.00023	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CB—pancreatic cancer	1.55e-05	0.00023	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—pancreatic cancer	1.54e-05	0.000228	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SRC—pancreatic cancer	1.49e-05	0.00022	CbGpPWpGaD
Pralatrexate—DHFR—Disease—STAT3—pancreatic cancer	1.43e-05	0.000212	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NRAS—pancreatic cancer	1.43e-05	0.000212	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CB—pancreatic cancer	1.35e-05	0.000201	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—pancreatic cancer	1.34e-05	0.000199	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTEN—pancreatic cancer	1.34e-05	0.000199	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—pancreatic cancer	1.33e-05	0.000197	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TGFB1—pancreatic cancer	1.33e-05	0.000197	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—pancreatic cancer	1.3e-05	0.000193	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—pancreatic cancer	1.23e-05	0.000182	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTEN—pancreatic cancer	1.17e-05	0.000173	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CA—pancreatic cancer	1.13e-05	0.000167	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HRAS—pancreatic cancer	1.05e-05	0.000155	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CA—pancreatic cancer	9.46e-06	0.00014	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AKT1—pancreatic cancer	9.23e-06	0.000137	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CA—pancreatic cancer	8.26e-06	0.000122	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKT1—pancreatic cancer	7.73e-06	0.000114	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKT1—pancreatic cancer	6.75e-06	9.99e-05	CbGpPWpGaD
